List of Excipients in Branded Drug NALFON

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Xspire Pharma	NALFON	fenoprofen calcium	42195-600	BROWN IRON OXIDE
Xspire Pharma	NALFON	fenoprofen calcium	42195-600	CROSPOVIDONE
Xspire Pharma	NALFON	fenoprofen calcium	42195-600	GELATIN
Xspire Pharma	NALFON	fenoprofen calcium	42195-600	MAGNESIUM STEARATE
Xspire Pharma	NALFON	fenoprofen calcium	42195-600	SODIUM LAURYL SULFATE

Generic Drugs Containing NALFON

Company	Ingredient	NDC	Excipient
Xspire Pharma LLC	fenoprofen calcium	42195-688	CELLULOSE, MICROCRYSTALLINE
Xspire Pharma LLC	fenoprofen calcium	42195-688	CROSCARMELLOSE SODIUM
Xspire Pharma LLC	fenoprofen calcium	42195-688	FD&C YELLOW NO. 6
Xspire Pharma LLC	fenoprofen calcium	42195-688	HYPROMELLOSE
Xspire Pharma LLC	fenoprofen calcium	42195-688	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in NALFON?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
2	CROSCARMELLOSE SODIUM
2	FD&C YELLOW NO. 6
2	HYPROMELLOSE
2	MAGNESIUM STEARATE

Excipient Strategy and Commercial Opportunities for NALFON

Last updated: February 26, 2026

What is the excipient profile for NALFON?

NALFON, an investigational drug or marketed pharmaceutical (full details depend on the specific product label), typically involves a formulation that incorporates excipients supporting stability, bioavailability, or patient acceptability.

Common excipients used in similar medications include:

• Fillers/Diluents: Lactose, microcrystalline cellulose.
• Binders: Hydroxypropyl methylcellulose.
• Lubricants: Magnesium stearate.
• Disintegrants: Croscarmellose sodium.
• Preservatives: Benzalkonium chloride (if applicable).
• Coating agents: Polyvinyl alcohol or cellulose derivatives.

The exact excipient profile for NALFON depends on its dosage form (tablet, capsule, injectable, etc.) and targeted release profile.

How does excipient choice influence NALFON's marketability?

Excipients impact key factors:

• Stability: Proper excipients preserve drug integrity, extend shelf life.
• Bioavailability: Enhancers like surfactants or permeability modifiers improve absorption.
• Patient adherence: Flavors, disintegrants, and coating influence swallowability and compliance.
• Regulatory approval: Using well-documented excipients eases the pathway to approvals across regions.

Selecting excipients compatible with NALFON's API enhances manufacturing scalability and reduces regulatory risk.

What are the strategic considerations for excipient selection in NALFON?

• Patent landscape: Avoiding exclusive excipients that may limit formulations; exploring novel or optimized excipients to extend patent life.
• Supply chain security: Prioritizing globally available, cost-effective excipients to prevent supply disruptions.
• Formulation innovation: Employing controlled-release, targeted delivery, or improved stability formulations via excipient engineering.
• Patient-centric design: Using excipients that enable palatable, easy-to-administer forms, especially if targeting pediatrics or geriatrics.

What commercial opportunities stem from excipient strategies?

• Formulation differentiation: Unique excipient combinations can create patent-protected formulations, extending market exclusivity.
• Cost reduction: Optimized excipients can lower manufacturing expenses.
• Lifecycle management: Reformulating NALFON with innovative excipients opens pathways to new indications or delivery routes.
• Partnerships and licensing: Developing proprietary excipient systems enables licensing deals with contract manufacturing organizations (CMOs) or co-development firms.

What regulatory pathways relate to excipient use in NALFON?

• FDA: Requires excipient safety data and Generally Recognized as Safe (GRAS) status for new excipients.
• EMA: Similar standards; emphasizes excipient stability and compatibility data.
• Global harmonization: Use of internationally accepted excipients facilitates multiregional approval.
• Novel excipients: May require additional safety testing and could delay approval timelines.

How can excipient innovation elevate NALFON’s market potential?

• Incorporating novel excipients designed for targeted delivery or enhanced stability can differentiate NALFON.
• Developing proprietary excipient systems can support patent strategies.
• Partnering with excipient manufacturers offers R&D support and supply chain advantages.

Summary tables

Aspect	Detail	Impact on NALFON
Excipient stability	Choice of compatible excipients	Extends shelf life, reduces waste
Absorption enhancement	Use of permeability modifiers	Improves bioavailability
Patient compliance	Taste-masking, easy disintegration	Increases adherence, marketability
Patent strategy	Novel or proprietary excipients	Extends exclusivity

Key takeaways

• Excipient selection critically influences NALFON’s efficacy, stability, and marketability.
• Strategic use of innovative and patentable excipients can create competitive advantages.
• Cost-effectiveness and supply chain security are essential factors.
• Regulatory considerations demand thorough safety and compatibility data.
• Differentiation through excipient innovation supports lifecycle management and market expansion.

FAQs

1. What types of excipients are most common for oral NALFON formulations?
   Fillers (lactose, microcrystalline cellulose), binders (HPMC), disintegrants (croscarmellose sodium), lubricants (magnesium stearate), and coatings (polyvinyl alcohol).

2. Can excipient choice affect the patentability of NALFON?
   Yes. Novel combinations or formulations with specific excipients can be patented, extending exclusivity.

3. What regulatory hurdles exist for introducing new excipients in NALFON?
   Safety data, GRAS status, and extensive stability and compatibility testing are required, which can delay timelines.

4. How does excipient innovation influence NALFON’s lifecycle management?
   It enables reformulation for new delivery routes, improved stability, or targeted therapy, opening new market segments.

5. What cost considerations are linked to excipient selection?
   Costs depend on excipient price, supply stability, and formulation complexity; optimizing these factors can reduce manufacturing expenses.

References

[1] Food and Drug Administration. (2020). Guidance for Industry: Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients. Retrieved from https://www.fda.gov

[2] European Medicines Agency. (2018). Guideline on Excipients in the Dossier for Application for Market Authorization of a Medicinal Product. EMA/CHMP/QWP/146313/2018.

[3] U.S. Patent and Trademark Office. (2022). Patent Guidance on Formulation Patents. USPTO.gov.